By Christy Santhosh Oct 22 (Reuters) - AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps ...
Clinical Trials Arena on MSN
AbbVie’s skin disease drug posts Phase III win as market competition heats up
This late-stage readout comes as companies explore the potential of novel mechanisms of action in HS.
Introduction: Skin diseases also affect the mindI'm so itchy that I can't sleep at night.I'm so self-conscious about my acne that I don't want to face people.My child's eczema won't get better, and ...
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late ...
A targeted antibody that blocks plasmacytoid dendritic cells clears skin in patients with moderate-to-severe cutaneous lupus ...
It has saved my time a lot, also my back pain has reduced.It saved me a lot of time. Also, my back pain has decreased.These ...
Symptoms are often mistaken for irritation, thrush or an STI, delaying proper treatment. Campaigners say the taboo around ...
Fatty liver disease often develops without obvious symptoms, so a person’s appearance is not a reliable way to identify it.
A protein best known for its role in Parkinson’s disease may also help melanoma cells survive. Researchers at Oregon Health & ...
Of the 58 countries that reported climate-associated effects, 81% said heat rashes were increasing, while 75.9% reported growth in inflammatory skin diseases. Infectious diseases also showed a change ...
Pollutant residue on clothes may cause irritation such as itchiness or redness, especially in people with eczema or sensitive ...
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results